Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best US stocks to buy under $50. On January 23, Cantor Fitzgerald reaffirmed its Overweight rating on Vaxcyte Inc. (NASDAQ:PCVX), keeping a positive view as the company advances its vaccine pipeline on schedule. The firm expects topline results from the Phase 3 OPUS-1 trial in late 2026, with an adult BLA filing planned for 2027.

It also noted progress in other studies: OPUS-2 has started dosing, OPUS-3 will begin in early 2026, and both should report results in 2027. Meanwhile, the infant Phase 2 VAX-31 study is on track, with key readouts expected by mid-2027.

Earlier on January 6, Evercore ISI reiterated an Outperform rating on Vaxcyte Inc., impressed by the CDC’s changes to childhood vaccination recommendations.

The positive stance comes from the CDC removing blanket recommendations for several vaccines, including Flu, COVID-19, and Hepatitis B. In addition, recommendations for childhood vaccinations, such as measles, polio, tetanus, and HPV, among others, remain in place.

The company is well-positioned to benefit, as it is also developing pneumococcal conjugate vaccines (PCVs). That’s because vaccine-sceptic groups and the CDC have yet to target pneumococcal vaccines.

Meanwhile, Jefferies maintains a Buy rating on the stock with a $146 price target. The research firm has echoed the company’s prospects amid the Phase 3 VAX-31 adult trial. Designed to protect against 31 types of Streptococcus pneumonia, VAX 31 has already delivered topline results in Phase ½ clinical trials.

Vaxcyte Inc. (NASDAQ:PCVX) has already met non-inferiority and superiority endpoints in the trials, thus on course to become the new standard for adult pneumococcal vaccination and consolidate market share against competing vaccines.

While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.